Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
AC Immune’s stock fell 9 percent on the news that the company’s Phase II Lauriet study of the investigational anti-Tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer’s disease (AD) did not meet all endpoints.
A new study suggests that some patients could see a decline in cognition that is equivalent to the brain aging approximately 10 years.
An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
A study of more than a thousand former professional soccer players has uncovered significantly more deaths from brain disease than among non-players.
Hearing loss in middle age is associated with higher odds of cognitive decline and dementia in later years, suggests a large study in Taiwan.
